Elucidating the role of the Branched Chain Aminotransferases (BCATc and BCATm) as novel metabolic checkpoints of anti-lymphoma T cell immunity
Date Published March 11, 2026
Elucidating BCATc and BCATm roles as metabolic checkpoints of anti-lymphoma T cell immunity to therapy.
| This project, focuses on defining how two key enzymes that regulate branched-chain amino acid metabolism influence T cell function in the context of lymphoma. The work addresses a critical intersection between cellular metabolism and immune control of cancer, aiming to clarify whether BCATc and BCATm act as metabolic checkpoints that shape T cell activation, differentiation and anti-tumor responses. By interrogating the contributions of these aminotransferases to the metabolic programs of T cells that encounter lymphoma, the project seeks foundational insight into how nutrient-handling pathways can enhance or constrain effective anti-lymphoma immunity. The study will explore the biological roles of BCATc and BCATm in T cells exposed to lymphoma antigens and tumor microenvironmental conditions. The research will consider how branched-chain amino acid turnover mediated by these enzymes affects T cell energetics, biosynthetic capacity, signaling and effector functions—elements that collectively determine the potency of anti-tumor responses. The project frames BCATc and BCATm as potential metabolic checkpoints, conceptually similar to immune checkpoints but operating at the level of metabolic regulation. Identifying such checkpoints could reveal novel levers to reprogram T cell metabolism toward sustained anti-lymphoma activity. The expected contributions of this work are multifold. Mechanistically, the project aims to map relationships between BCAT activity and T cell phenotypes relevant to lymphoma control, including proliferation, cytokine production, cytotoxicity and memory formation. Translationally, delineating how BCATc and BCATm modulate T cell responses may point to metabolic interventions—small molecules, dietary modifications, or combination strategies with immunotherapies—that enhance T cell-mediated clearance of lymphoma. Conceptually, the study broadens the understanding of how amino acid metabolism intersects with immune regulation in cancer, offering a metabolic perspective on immune evasion and immune potentiation. The significance of investigating BCATc and BCATm as metabolic checkpoints lies in the potential to expand the repertoire of targets for immunomodulation. While immune checkpoint blockade has transformed treatment for several cancers, many patients with hematologic malignancies such as lymphoma do not achieve durable responses. Metabolic checkpoints represent an emerging class of modulators that could complement existing therapies by optimizing T cell fitness within the nutrient-competitive tumor microenvironment. Outcomes from this project could therefore inform future preclinical and clinical strategies that aim to boost anti-lymphoma immunity by adjusting metabolic constraints. Overall, this research initiative positions BCATc and BCATm at the crossroads of metabolism and immunity and aims to generate rigorous, hypothesis-driven evidence about their roles in anti-lymphoma T cell function. By elucidating these relationships, the project aspires to identify metabolic vulnerabilities and opportunities that might be translated into new approaches to enhance immune-mediated control of lymphoma. |
Learn more
COM Affiliation
Funding Amount
$443,548
Funding Type
Federal Government Award
Update This Listing
Help us provide the most up-to-date information about this project.
Contact UsQuestions?
For questions about these research projects please email us.
Contact Us